Kennedy Keith sold $4.8M of CDNA

Kennedy Keith (CFO & COO) sold 61,961 shares of CareDx, Inc. (CDNA) at an average of $77.82 ($76.55–$83.60, $4.82M total) across 8 trades on 2026-11-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kennedy Keith
Published Nov 9, 2026, 11:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 11:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CDNA
Bearish
medium confidence
Mentioned
$CDNA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CDNABearishLow
01

Why it matters

The disclosed sale reduces insider ownership and may be interpreted as a lack of confidence, potentially prompting short sellers.

02

Market read

The filing provides fresh, material information about insider activity that could affect CDNA's short‑term price.

03

What to watch

The CFO may be diversifying holdings; no change in company fundamentals is indicated.

Relevance 5/10Novelty 7/10Timing: post‑market today

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$CDNABearishMedium confidence
Context

CFO Kennedy Keith sold 61,961 shares for $4.8M via a 10b5‑1 plan, reducing his stake to 199,147 shares.

Expected impact

likely downward pressure as the market prices in the insider sell.

Evidence & confidence

A $4.8M sale by a senior officer is material but not large enough to trigger a major move; traders may watch for further insider activity.

Market effects

Minimal impact on the broader biotech sector; the sale is company‑specific.

Limited to U.S. markets where CDNA trades.

Low global relevance.

Counterpoint

The sale could be a routine liquidity event under a pre‑arranged plan, not a negative signal.

Key entities

  • CareDx, Inc.

    Biotech firm listed on NASDAQ under CDNA.

  • Kennedy Keith

    CFO & COO of CareDx, reporting the insider sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CRWVMed

Futures Rise As CoreWeave Calms Debt Jitters, Sparking AI Rebound; Oil Jumps On Hormuz Mines

US futures rise as CoreWeave (CRWV) boosts its revenue forecast, easing debt concerns. AI sector gains momentum with reports of Anthropic's potential $1.5T IPO and OpenAI's $10B quarterly revenue. Nasdaq futures recover Tuesday's losses, while Treasuries near 5% on 10Y. Oil jumps on Strait of Hormuz tensions. CoreWeave shares up 15% premarket. NVDA +5.1%, TSLA +2%, GOOGL +1.2%.

$CDNALow

Why CareDx Stock Soared Today

CareDx (CDNA) shares rose 22% after Q3 revenue surged 39% YoY to $139M, driven by 65% growth in testing services. Testing volumes increased 51% to 75,900, aided by the Naveris acquisition. EBITDA doubled to $30M. The company raised full-year revenue guidance to $525M and adjusted EBITDA targets to $90M-$100M, citing growing interest in precision medicine diagnostics.

$CDNAHighAI 8/10

CareDx Soars 20% on Big Q3 Beat and Guidance Raise

CareDx's shares rose 20% after Q3 revenue increased 39% to $139M, surpassing expectations. The company raised 2026 revenue guidance to $520M-$530M. Adjusted EBITDA doubled to $30M. Natera, a competitor, reports next week, which may indicate market growth or share shifts.